The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar

Journal of Clinical Pharmacology

Volumn 53, Issue 5, 2013, Pages 540-549

  Kosoglou, Teddy ^a   Statkevich, Paul ^a   Kumar, Bharath ^a   Xuan, Fengjuan ^a   Schiller, James E ^a   Johnson Levonas, Amy O ^a   Young, Sophia ^a   Cutler, David L ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug drug interaction; Ketoconazole; PAR 1; Pharmacokinetics; Rifampin; SCH 530348; Vorapaxar

Indexed keywords

KETOCONAZOLE; PLACEBO; RIFAMPICIN; VORAPAXAR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PETECHIA; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TREATMENT DURATION;

ADULT; AGED; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; KETOCONAZOLE; LACTONES; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RIFAMPIN; YOUNG ADULT;

EID: 84880165865     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.20     Document Type: Article

References (16)

1. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51:3061-3064. (Pubitemid 351821864)
2. Chintala M, Vemulapalli S, Kurowski S, et al. SCH 530348, a novel oral antiplatelet agent, demonstrated no bleeding risk alone or in combination with aspirin and clopidogrel in Cynomolgus monkeys [abstract]. Atheroscler Thromb Vasc Biol. 2008;28:e138-e139.
3. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012;68:249-258.
4. Tricoci P, Huang Z, Held C, et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012;366: 20-33.
5. Morrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366:1404-1413.
6. Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (Vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011;39:30-38.
7. Statkevich P, Kosoglou T, Kumar B, et al. Pharmacokinetics of vorapaxar and its metabolite SCH2046273 (M20) following administration in Chinese and US subjects [abstract]. Clin Pharmacol Ther. 2012;91:S54.
8. Kosoglou T, Kraft WK, Kumar B, et al. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease. Eur J Clin Pharmacol. 2012;68:1049-1056.
9. Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmer's pioneering ideas to modern concepts. Drug Metab Rev. 2004;36:497-509. (Pubitemid 39456439)
10. Reitman ML, Chu X, Cai X, et al. Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther. 2011;89:234-242.
11. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002;46:160-165. (Pubitemid 34031618)
12. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol. 1998;54:53-58. (Pubitemid 28189400)
13. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66:461-471.
14. Feng HJ, Huang SL, Wang W, Zhou HH. The induction effect of rifampicin on activity of mephenytoin 4'-hydroxylase related to M1 mutation of CYP2C19 and gene dose. Br J Clin Pharmacol. 1998;45:27-29. (Pubitemid 28062850)
15. Zhou HH, Anthony LB, Wood AJ, Wilkinson GR. Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. Br J Clin Pharmacol. 1990;30:471-475. (Pubitemid 20281115)
16. Kosoglou T, Reyderman L, Kasserra C et al. No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects. Eur J Clin Pharmacol. 2012;68:291-300.